Developer docs
API playgroundTry for free, no card

Search company profiles

Nebula Genomics

Full company profile

uuid0002kjc

Namestring
Nebula Genomics
Legal namestring
Nebula Genomics, Inc.
Websiteurl
nebula.org
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Nebula Genomics, founded in 2018 by Harvard Medical School Professor of Genetics Dr. George Church and now operated as a service of ProPhase Labs, Inc., provides whole genome sequencing (WGS) to both individual consumers and enterprise customers. Its flagship consumer product, DNA Complete, decodes 100% of a user's DNA from a saliva sample and returns more than 350 personalized health, trait, ancestry, and oral microbiome reports that are continuously updated as new genetic discoveries emerge, marketed in contrast to SNP-chip tests from 23andMe and Ancestry that cover approximately 1% of the genome. Pricing for DTC kits starts at $249 for 30x clinical-grade WGS, with a subscription layer providing ongoing access to the Nebula Library and ancestry reports.

Short descriptiontext

Nebula Genomics is a U.S.-based whole genome sequencing company offering DTC DNA Complete kits and enterprise sequencing services to pharma, biotech, academic, and population health customers, using a CLIA-certified lab and blockchain-secured data handling.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGarden City, United States
HQ citystring
Garden City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
whole genome sequencing, genetic testing services, personal genomics, genomic data platform, direct-to-consumer dna
Industry3 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Genetic Testing Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1DNA Testing Kits
TypeOne Time License
Description

One-time purchase of DNA collection kits for whole genome sequencing. Consumers purchase the kit, submit saliva sample, and receive genetic reports. Pricing starts at $249 for 30x WGS options with all reports included.

nebula.org
2Subscription/Membership
TypeSubscription Recurring
Description

Ongoing membership providing continuous access to the Nebula Library, ancestry reports, traits, and oral microbiome analysis. Subscription fees are charged for renewal periods with specific terms around cancellation.

nebula.org
3Enterprise Sequencing Services
TypeProfessional Services
Description

B2B whole genome sequencing services for pharma, biotech, academic research, and population health organizations. Services include sample collection kits, custom reports (400+ existing or custom panels), white-label solutions, and bioinformatics analysis.

nebula.org
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details5 tiers
130x Whole Genome Sequencing - Starting price for clinical-grade WGS
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Starts at $249 with all reports included in one price. 30x coverage provides clinical-grade sequencing suitable for research and diagnostic applications.

mynucleus.com
2100x Whole Genome Sequencing - Ultra-deep sequencing option
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

100x WGS option available, providing ultra-deep sequencing for somatic mutation detection and rare variant discovery. Priced higher than 30x tier.

mynucleus.com
31x WGS Enterprise - Cost-effective population screening
ModelUsage-basedBilling cadenceMulti-year contract
Notes

Cost-effective at scale, imputation-ready output. Ideal for biobanks and cohort studies. Priced per sample with volume discounts for large-scale projects.

nebula.org
430x WGS Enterprise - Clinical-grade research sequencing
ModelUsage-basedBilling cadenceMulti-year contract
Notes

High-confidence variant calling for SNVs, indels, and structural variants. CRAM and VCF deliverables included. Quote-based pricing.

nebula.org
5100x WGS Enterprise - Ultra-deep rare disease research
ModelUsage-basedBilling cadenceMulti-year contract
Notes

3x deeper than industry standard for low-frequency variant detection. Rare disease research ready. Quote-based pricing.

nebula.org
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 record
1DNA Complete by Nebula Genomics
Description

The company's flagship whole genome sequencing product offering that analyzes 100% of DNA, providing health, traits, ancestry, and oral microbiome reports.

nebula.org
Core offering1 text field

Nebula Genomics offers whole genome sequencing (WGS) through its DNA Complete product, decoding 100% of a customer's DNA via an at-home saliva collection kit and delivering 350+ personalized health, ancestry, trait, and oral microbiome reports with continuous updates. The company also provides enterprise B2B genomic sequencing services from a CLIA-certified U.S. laboratory, supplying pharma, biotech, academic, and population-health clients with flexible 1x/30x/100x WGS tiers, custom and white-label reports, and bioinformatics analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 350+ personalized health reports across major health categories
+2 more records
Product and service4 records
1DNA Complete by Nebula Genomics
CategoryDirect-to-consumer genetic testing
Description

Direct-to-consumer at-home whole genome sequencing kit that decodes 100% of a customer's DNA from a saliva sample, delivering 350+ personalized health, ancestry, trait, and oral microbiome reports with continuous updates as new genetic discoveries emerge. Targeted at individual consumers seeking comprehensive personal genomic insights.

2Nebula Genomics Enterprise Sequencing Services
CategoryEnterprise genomic sequencing services
Description

B2B whole genome sequencing services from a CLIA-certified U.S. laboratory, offered in 1x, 30x (clinical-grade), and 100x (ultra-deep) tiers for pharma, biotech, academic research, and population-health organizations. Includes chain-of-custody sample collection kits, 400+ curated reports, custom panel development, white-label solutions, and bioinformatics deliverables (CRAM, VCF).

3Nebula Research Library
CategoryGenomic research content and reports
Description

Curated library of 400+ DNA reports based on peer-reviewed scientific publications, covering genetic conditions and traits such as eczema, vitamin D levels, and macular degeneration, available as part of DNA Complete and enterprise sequencing offerings.

4Nebula Genomics Membership / Subscription
CategorySubscription / Membership
Description

Recurring membership providing continuous access to the Nebula Library, ancestry reports, trait analyses, oral microbiome results, and continuous report updates as new genetic discoveries emerge, with subscription billing and defined cancellation terms.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Dante Labs and Nebula Genomics announced a merger, combining their whole genome sequencing capabilities and market positions in the consumer genomics space. This consolidation reflects ongoing industry trends toward merger and acquisition activity in the genetic testing sector.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large clinical genetics company offering a broad menu of genetic tests across hereditary cancer, reproductive health, and rare diseases. Broader incumbent with overlapping enterprise and clinical genomics business though not focused on DTC or whole genome.

TypeDirect peer
Description

Sequencing-centric platform combining next-generation sequencing with a marketplace of DNA-powered apps. Comparable in offering WGS infrastructure and consumer/enterprise applications, though organized around an app ecosystem model.

TypeDirect peer
Description

Direct-to-consumer genetic testing leader offering health and ancestry reports. Directly comparable as a consumer-facing DNA testing brand, though 23andMe uses SNP-chip arrays (~1% of DNA) versus Nebula's WGS; serves the same customer need for personal genetic insights.

TypeBroad incumbent
Description

Global genomics conglomerate with WGS services through BGI Genomics and the MGI sequencing instrument platform. Comparable in large-scale sequencing capacity and enterprise B2B genomics services, though far broader in scope and geographic reach.

5Ancestry
TypeDirect peer
Description

Major DTC genetic testing brand focused on ancestry and family history. Directly comparable consumer genomics offering, similarly relying on SNP-chip arrays (~1% of DNA) and competing for the same consumer attention and wallet share.

TypeDirect peer
Description

Whole genome sequencing provider offering both consumer and clinical/lifestyle products, including myGenome. Direct competitor in the WGS consumer space with similar positioning around comprehensive genomic analysis.

TypeDirect peer
Description

Whole genome sequencing-based health intelligence company founded by J. Craig Venter offering comprehensive genomic analysis to consumers and enterprise. Direct WGS-based competitor with similar health-focused value proposition.

TypeDirect peer
Description

Whole genome sequencing DTC provider and direct competitor; the two companies announced a merger in 2025. Highly comparable business model, sequencing technology tiering, and customer segments, making this the most direct peer.

TypeEmerging player
Description

Clinical-grade genetic testing company offering hereditary cancer screening, pharmacogenomics, and population genomics programs. Comparable enterprise/clinical genomic services capability, though more focused on panel-based testing than WGS.

TypeDirect peer
Description

DTC genetic testing company with strong European presence offering ancestry and health DNA kits. Comparable as a consumer-facing DNA testing brand competing for the same international customer base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nebula Genomics

Genetic Testing Servicesnebula.org

Nebula Genomics is a U.S.-based whole genome sequencing company offering DTC DNA Complete kits and enterprise sequencing services to pharma, biotech, academic, and population health customers, using a CLIA-certified lab and blockchain-secured data handling.

What Nebula Genomics does

Nebula Genomics, founded in 2018 by Harvard Medical School Professor of Genetics Dr. George Church and now operated as a service of ProPhase Labs, Inc., provides whole genome sequencing (WGS) to both individual consumers and enterprise customers. Its flagship consumer product, DNA Complete, decodes 100% of a user's DNA from a saliva sample and returns more than 350 personalized health, trait, ancestry, and oral microbiome reports that are continuously updated as new genetic discoveries emerge, marketed in contrast to SNP-chip tests from 23andMe and Ancestry that cover approximately 1% of the genome. Pricing for DTC kits starts at $249 for 30x clinical-grade WGS, with a subscription layer providing ongoing access to the Nebula Library and ancestry reports.

Nebula Genomics firmographics

Firmographics
Name
Nebula Genomics
Legal name
Nebula Genomics, Inc.
Website
https://nebula.org
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Nebula Genomics is a U.S.-based whole genome sequencing company offering DTC DNA Complete kits and enterprise sequencing services to pharma, biotech, academic, and population health customers, using a CLIA-certified lab and blockchain-secured data handling.
Ownership category
akta.pro rank

Nebula Genomics industry classification

Industry
Product category
Genetic Testing Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Whole genome sequencing
  • Genetic testing services
  • Personal genomics
  • Genomic data platform
  • Direct-to-consumer dna

Where Nebula Genomics is headquartered

Location

Headquarters

HQ city
Garden City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nebula Genomics business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. DNA Testing Kits: One-time purchase of DNA collection kits for whole genome sequencing. Consumers purchase the kit, submit saliva sample, and receive genetic reports. Pricing starts at $249 for 30x WGS options with all reports included.
  2. Subscription/Membership: Ongoing membership providing continuous access to the Nebula Library, ancestry reports, traits, and oral microbiome analysis. Subscription fees are charged for renewal periods with specific terms around cancellation.
  3. Enterprise Sequencing Services: B2B whole genome sequencing services for pharma, biotech, academic research, and population health organizations. Services include sample collection kits, custom reports (400+ existing or custom panels), white-label solutions, and bioinformatics analysis.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-go30x Whole Genome Sequencing - Starting price for clinical-grade WGS
One time/ perpetual licensePay-as-you-go100x Whole Genome Sequencing - Ultra-deep sequencing option
Usage-basedMulti-year contract1x WGS Enterprise - Cost-effective population screening
Usage-basedMulti-year contract30x WGS Enterprise - Clinical-grade research sequencing
Usage-basedMulti-year contract100x WGS Enterprise - Ultra-deep rare disease research

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Nebula Genomics product offering

Product offering

Core offering

Nebula Genomics offers whole genome sequencing (WGS) through its DNA Complete product, decoding 100% of a customer's DNA via an at-home saliva collection kit and delivering 350+ personalized health, ancestry, trait, and oral microbiome reports with continuous updates. The company also provides enterprise B2B genomic sequencing services from a CLIA-certified U.S. laboratory, supplying pharma, biotech, academic, and population-health clients with flexible 1x/30x/100x WGS tiers, custom and white-label reports, and bioinformatics analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • DNA Complete by Nebula Genomics: The company's flagship whole genome sequencing product offering that analyzes 100% of DNA, providing health, traits, ancestry, and oral microbiome reports.

Products and services

  • DNA Complete by Nebula Genomics Direct-to-consumer at-home whole genome sequencing kit that decodes 100% of a customer's DNA from a saliva sample, delivering 350+ personalized health, ancestry, trait, and oral microbiome reports with continuous updates as new genetic discoveries emerge. Targeted at individual consumers seeking comprehensive personal genomic insights.
  • Nebula Genomics Enterprise Sequencing Services B2B whole genome sequencing services from a CLIA-certified U.S. laboratory, offered in 1x, 30x (clinical-grade), and 100x (ultra-deep) tiers for pharma, biotech, academic research, and population-health organizations. Includes chain-of-custody sample collection kits, 400+ curated reports, custom panel development, white-label solutions, and bioinformatics deliverables (CRAM, VCF).
  • Nebula Research Library Curated library of 400+ DNA reports based on peer-reviewed scientific publications, covering genetic conditions and traits such as eczema, vitamin D levels, and macular degeneration, available as part of DNA Complete and enterprise sequencing offerings.
  • Nebula Genomics Membership / Subscription Recurring membership providing continuous access to the Nebula Library, ancestry reports, trait analyses, oral microbiome results, and continuous report updates as new genetic discoveries emerge, with subscription billing and defined cancellation terms.

Quantifiable outcome

  • 350+ personalized health reports across major health categories
  • +2 more outcomes

Companies that use Nebula Genomics

Customer profile

Segments5 records

Ideal customer profiles4 records

Nebula Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Nebula Genomics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Dante LabsmajorStrategic or Co-development PartnerDante Labs and Nebula Genomics announced a merger, combining their whole genome sequencing capabilities and market positions in the consumer genomics space. This consolidation reflects ongoing industry trends toward merger and acquisition activity in the genetic testing sector.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Nebula Genomics competitors and assessment

Company assessment

Broad incumbents

  • Invitae: Large clinical genetics company offering a broad menu of genetic tests across hereditary cancer, reproductive health, and rare diseases. Broader incumbent with overlapping enterprise and clinical genomics business though not focused on DTC or whole genome.
  • BGI Group: Global genomics conglomerate with WGS services through BGI Genomics and the MGI sequencing instrument platform. Comparable in large-scale sequencing capacity and enterprise B2B genomics services, though far broader in scope and geographic reach.

Direct peers

  • Helix: Sequencing-centric platform combining next-generation sequencing with a marketplace of DNA-powered apps. Comparable in offering WGS infrastructure and consumer/enterprise applications, though organized around an app ecosystem model.
  • 23andMe: Direct-to-consumer genetic testing leader offering health and ancestry reports. Directly comparable as a consumer-facing DNA testing brand, though 23andMe uses SNP-chip arrays (~1% of DNA) versus Nebula's WGS; serves the same customer need for personal genetic insights.
  • Ancestry: Major DTC genetic testing brand focused on ancestry and family history. Directly comparable consumer genomics offering, similarly relying on SNP-chip arrays (~1% of DNA) and competing for the same consumer attention and wallet share.
  • Veritas Genetics: Whole genome sequencing provider offering both consumer and clinical/lifestyle products, including myGenome. Direct competitor in the WGS consumer space with similar positioning around comprehensive genomic analysis.
  • Human Longevity Inc. Whole genome sequencing-based health intelligence company founded by J. Craig Venter offering comprehensive genomic analysis to consumers and enterprise. Direct WGS-based competitor with similar health-focused value proposition.
  • Dante Labs: Whole genome sequencing DTC provider and direct competitor; the two companies announced a merger in 2025. Highly comparable business model, sequencing technology tiering, and customer segments, making this the most direct peer.
  • MyHeritage: DTC genetic testing company with strong European presence offering ancestry and health DNA kits. Comparable as a consumer-facing DNA testing brand competing for the same international customer base.

Emerging players

  • Color Genomics: Clinical-grade genetic testing company offering hereditary cancer screening, pharmacogenomics, and population genomics programs. Comparable enterprise/clinical genomic services capability, though more focused on panel-based testing than WGS.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Nebula Genomics social profiles

Digital presence

Nebula Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nebula Genomics leadership team

Management profile

Number of profiles

Profiles4 records

Nebula Genomics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nebula Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nebula Genomics

What does Nebula Genomics do?

Nebula Genomics offers whole genome sequencing (WGS) through its DNA Complete product, decoding 100% of a customer's DNA via an at-home saliva collection kit and delivering 350+ personalized health, ancestry, trait, and oral microbiome reports with continuous updates. The company also provides enterprise B2B genomic sequencing services from a CLIA-certified U.S. laboratory, supplying pharma, biotech, academic, and population-health clients with flexible 1x/30x/100x WGS tiers, custom and white-label reports, and bioinformatics analysis.

Is Nebula Genomics a public or private company?

Nebula Genomics is a private company. It is classified as corporate owned and is currently operating.

When was Nebula Genomics founded?

Nebula Genomics was founded in 2018. It employs 11 to 50 people.

Where is Nebula Genomics based?

Nebula Genomics is headquartered in Garden City, United States, in the North America region.

How does Nebula Genomics make money?

Three revenue lines are on record. DNA Testing Kits are the primary driver. The others are subscription/Membership and enterprise Sequencing Services.

Who are Nebula Genomics's main competitors?

Broad incumbents on record are Invitae and BGI Group. Direct peers are Helix, 23andMe, Ancestry, Veritas Genetics, Human Longevity Inc., Dante Labs and MyHeritage. Color Genomics is listed as an emerging player.

Does Nebula Genomics have an API?

No public API is recorded for Nebula Genomics.

What industry is Nebula Genomics in?

Nebula Genomics's product category is Genetic Testing Services. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ZDNET JapanI read the fine print on at-home DNA and health tests - watch out for these risksA ZDNET investigative review examined the privacy policies and practices of 10 at-home direct-to-consumer (DTC) DNA and health testing companies, finding widespread gaps in HIPAA protections, inconsistent use of regulatory language, and ambiguous data sharing practices with third parties for marketing and research purposes. The investigation revealed that companies like LetsGetChecked, SiPhox, and Nebula Genomics may share de-identified or aggregated genetic data with third parties, while experts warn that supposedly anonymized genomic data can often be re-identified and linked back to individuals. Consumer advocates and bioethicists quoted in the article argue that the industry lacks consistent FDA oversight, that follow-up medical care and genetic counseling vary widely, and that federal laws like GINA do not fully protect consumers from genetic discrimination by life, long-term care, or disability insurers.GrandresearchstoreArtificial Intelligence Protein Design Service Market ReportThe global AI Protein Design Service market is projected to grow from $1.812 billion in 2025 to $5.581 billion by 2032, representing a compound annual growth rate of 17.9%, driven by advancements in generative AI models such as AlphaFold 2 and RoseTTAFold that have improved protein structure prediction accuracy above 90%. Key players in the market include DeepMind, Generate Biomedicines, Insilico Medicine, Insitro, Arzeda, Atomwise, BioMap, and Nebula Genomics, with North America holding the dominant market share while Asia-Pacific is expected to witness the fastest growth. The market faces challenges including high computational costs, data quality issues, and a 35% shortfall in professionals skilled in both machine learning and protein biochemistry.Dna-StoryNebula Genomics review : What the experts say (2026)This article is a detailed expert review of Nebula Genomics, a DNA testing laboratory founded in 2018 by Dr. George Church of Harvard Medical School, evaluating its whole genome sequencing services, blockchain-based data protection, and three pricing tiers (Standard at €93.56, Deep at €233, and Ultra Deep at €941). The review highlights the company's use of Illumina technology and partnership with BGI Group for DNA sequencing, achieving 4x to 100x accuracy through multiple genome examinations. Comparing Nebula Genomics against competitors such as MyHeritage, 23andMe, Quick DNA, EasyDNA, and Living DNA, the review finds the service offers solid genomic depth and confidentiality but notes drawbacks including 8-14 week result timeframes and mandatory paid subscriptions for ongoing access.MynucleusSequencing.com vs. Nebula Genomics: Which whole-genome sequencing test to pick?This article compares Sequencing.com and Nebula Genomics, two direct-to-consumer companies offering whole-genome sequencing (WGS) services for health, wellness, and ancestry insights. Sequencing.com provides a marketplace of third-party reports starting at $389 with physician-ordered tests, while Nebula Genomics offers 30x and 100x WGS options starting at $249 with all reports included in one price. The comparison covers key criteria including types of reports, quality, turnaround time (12–16 weeks for both), pricing models, privacy compliance, and user experience, with both companies receiving mixed customer reviews citing long wait times and service issues. The article also recommends Nucleus as a potentially superior alternative offering clinical-grade WGS testing at a single price point with easier-to-interpret reports.Market Research FuturePredictive Genetic Testing & Consumer/Wellness Genomics CompaniesThis market report covers multiple genetic testing companies announcing new products, strategic partnerships, and mergers in the consumer and wellness genomics space. Notable developments include Fulgent Genetics expanding its carrier screening panel, Helix launching a faster ancestry test, Color Genomics entering the gut-mind health market, Dante Labs merging with Nebula Genomics, 23andMe partnering with Mayo Clinic for research, and Invitae acquiring Genomic Health for $4 billion. These announcements collectively reflect ongoing consolidation and innovation across the genetic testing industry, with companies expanding their service offerings and research capabilities.DigitalroarDubai's Top 10 Healthcare Blockchain Companies in 2026Digitalroar Softlabs, a blockchain development company based in Dubai, has published a listicle ranking what it considers to be the top 10 blockchain healthcare development companies for 2026. The article discusses the benefits of blockchain technology for healthcare data security, including enhanced protection of patient records, reduced need for intermediaries, and improved authenticity in clinical research. The featured companies include Akiri, BurstlQ, Guardtime, ProCredEx, FarmaTrust, Nebula Genomics, Patientory, Sharecare, and Solve.Care, alongside the publishing company Digitalroar Softlabs.Nova One AdvisorGlobal Direct-to-Consumer Genetic Testing Market Size, Share, Forecast Report, 2024-2033The global direct-to-consumer genetic testing market is projected to grow from USD 1.94 billion in 2023 to USD 17.36 billion by 2033, representing a compound annual growth rate of 24.5%, driven by rising consumer interest in personalized health, decreasing sequencing costs, and increased adoption of preventive healthcare. North America held the largest market share at 61% in 2023, while Asia-Pacific emerges as the fastest-growing region. Key players including 23andMe, AncestryDNA, MyHeritage, Helix, and Nebula Genomics are driving innovation through subscription services, AI-powered heritage tools, and affordable whole genome sequencing, amid ongoing concerns over data privacy and regulatory frameworks.DnacompletePioneering Whole Genome Sequencing & InsightsNebula Genomics is marketing its DNA Complete service, which utilizes Whole Genome Sequencing to analyze 100% of a customer's DNA for health and ancestry insights. The company highlights its founder, Dr. George Church, and positions the product against competitors like 23andMe and Ancestry by emphasizing comprehensive data ownership and regular scientific updates.PixelPlex6 Blockchain Use Cases in Healthcare: A Detailed OverviewThe article outlines six key blockchain applications in healthcare, including patient record management, drug supply chain tracking, credential verification, genomic research, clinical trial security, and telemedicine. It cites market projections estimating the sector's value to grow from $0.76 billion in 2022 to $14.25 billion by 2032. The piece highlights specific companies such as BurstIQ, MediLedger, Nebula Genomics, and MedX as examples of firms implementing these decentralized solutions.openPR.comBlockchain in Genomics Market Outlook 2025-2035: Trends, Applications, and Strategic InsightsThe blockchain in genomics market is projected to grow from USD 37 million in 2024 to USD 4,455.9 million by 2035, a CAGR of 59.7%. Key players include Nebula Genomics, Lifebit Biotech, and EncrypGen, with applications in secure data sharing and patient consent management.